Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
630 stopped studies mapped to Malignant Hepatobiliary Neoplasm and descendants · 92% state a reason
Over the 630 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT02585687 | Liver Perfusion MRI With Quantification of Tumoral Perfusion for Early Assessment of the…(ETAFIRM) | N/A | terminated | Oct 23, 2015 | Hospices Civils de Lyon | problems with enrollment | Enrollment / accrual |
| NCT01489410 | Comparing Lipiodol/Ethanol With Drug-eluting Beads (DEB) for Hepatocellular Carcinoma | N/A | withdrawn | Dec 9, 2011 | University of Minnesota | Insufficient staff | Other (stated, no rule matched) |
| NCT01668017 | A Multicentre, Open Label, Phase 1 Trial in Japan of the Mitogen Activated Protein… | Phase 1 | terminated | Aug 17, 2012 | Merck KGaA, Darmstadt, Germany | The sponsor decided not to conduct the expansion part of trial (part 2) | Sponsor / business decision |
| NCT02821533 | Chemoembolization for Hepatocellular Carcinoma | Phase 2 | terminated | Jul 1, 2016 | Chinese University of Hong Kong | Poor case accrual | Enrollment / accrual |
| NCT01191385 | GIDEON Non-Nexavar Arm - HCC Patients Who Are Treated With Any Therapy Other Than Nexavar… | — | withdrawn | Aug 30, 2010 | Bayer | Study is officially cancelled bevore FPFV. | Other (stated, no rule matched) |
| NCT02959359 | DAA in the Risk of Recurrence After Curative Treatment of HCC | Phase 4 | withdrawn | Nov 9, 2016 | Taipei Veterans General Hospital, Taiwan | The supplies of study drug were halted by Gilead Sciences Ltd. | Other (stated, no rule matched) |
| NCT00386516 | Study to Test the Benefit and Safety of GM-CT-01 in Combination With 5-FU to Treat Bile… | Phase 2 | withdrawn | Oct 11, 2006 | Galectin Therapeutics Inc. | Financing and re-organization | Funding |
| NCT01419795 | Lenalidomide With or Without Rituximab in Treating Patients With Progressive or Relapsed… | Phase 2 | terminated | Aug 18, 2011 | Fred Hutchinson Cancer Center | Low accrual | Enrollment / accrual |
| NCT00085410 | Bortezomib in Treating Patients With Unresectable Locally Advanced or Metastatic… | Phase 2 | terminated | Jun 11, 2004 | National Cancer Institute (NCI) | The trial was discontinued early due to no confirmed partial responses. | Other (stated, no rule matched) |
| NCT00039078 | Radiolabeled Glass Beads (TheraSphere®) in Treating Patients With Primary Liver Cancer… | Phase 2 | withdrawn | Jan 27, 2003 | Allan Tsung | Record created in error - not a research study | Other (stated, no rule matched) |
| NCT00787787 | Sunitinib Malate and Capecitabine in Treating Patients With Unresectable or Metastatic… | Phase 2 | terminated | Nov 10, 2008 | University of Washington | not stated | Not stated |
| NCT02856568 | Ricolinostat, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With… | Phase 1 | withdrawn | Aug 5, 2016 | Mayo Clinic | Site dropped study | Other (stated, no rule matched) |
| NCT01303159 | Endoscopic Bipolar Radiofrequency Probe (ENDOHPB) in the Management of Unresectable Bile… | N/A | terminated | Feb 24, 2011 | Weill Medical College of Cornell University | EndoHPB probe is FDA approved and considered standard of care | Other (stated, no rule matched) |
| NCT01005875 | Stereotactic Radiation Therapy and Sorafenib in the Treatment of Hepatocellular Carcinoma(RAD 0901) | N/A | terminated | Nov 2, 2009 | University of Alabama at Birmingham | Sponsor(Bayer)did not wish to continue with study due to slow accrual. Therefore, there is… | Enrollment / accrual |
| NCT00524316 | Sunitinib and Chemoembolization in Treating Patients With Liver Cancer That Cannot Be… | Phase 2 | terminated | Sep 3, 2007 | Roswell Park Cancer Institute | low accrual | Enrollment / accrual |
| NCT01942083 | A Phase I, Open Label, Non Randomized, Multicenter, Dose Escalation Clinical Study to… | Phase 1 | terminated | Sep 13, 2013 | Korea Otsuka Pharmaceutical Co., Ltd. | Company decision | Sponsor / business decision |
| NCT00604266 | Coregistration of 18F-FDG-PET and MRI in the Staging of Potentially Resectable Hilar…(PET/MRCP) | — | withdrawn | Jan 30, 2008 | University of Toronto | not stated | Not stated |
| NCT01379521 | Safety and Efficacy of RAD001 + TACE in Localized Unresectable HCC(TRACER) | Phase 2 | terminated | Jun 23, 2011 | Novartis Pharmaceuticals | The study was terminated due to low enrollment. This resulted in the study being underpowered and… | Enrollment / accrual |
| NCT02227914 | Phase 1b/2 Study of Oprozomib in Combination With Sorafenib in Subjects With Advanced… | Phase 1 / Phase 2 | withdrawn | Aug 28, 2014 | Amgen | Study stopped due to administrative reasons | Other (stated, no rule matched) |
| NCT00455091 | A Phase III Study in Post-operative HBV-related Hepatocellular Carcinoma | — | terminated | Apr 3, 2007 | National Health Research Institutes, Taiwan | No cases enrollment | Enrollment / accrual |
| NCT01171482 | Comparison Study of Sorafenib and 5-fluorouracil/Mitomycin for Metastatic Hepatocellular… | Phase 2 | terminated | Jul 28, 2010 | Seoul National University Hospital | There were problems with national reimbursement policies. | Other (stated, no rule matched) |
| NCT02997956 | Study of Tocilizumab in Patients With Hepatocellular Carcinoma (HCC) Undergoing… | Phase 1 / Phase 2 | withdrawn | Dec 20, 2016 | University of Michigan Rogel Cancer Center | funding issues | Funding |
| NCT01543607 | Endoscopic Therapy of Malignant Bile Duct Strictures | N/A | terminated | Mar 5, 2012 | Massachusetts General Hospital | Lack of enrollment | Enrollment / accrual |
| NCT01849588 | HCV-RNA Kinetics During Sorafenib for Hepatocellular Carcinoma (HCC) | Phase 4 | terminated | May 8, 2013 | Massachusetts General Hospital | Slow Accrual | Enrollment / accrual |
| NCT02819869 | The Combination Effect of Statin Plus Metformin on Relapse-free | Phase 2 | terminated | Jun 30, 2016 | Taipei Medical University WanFang Hospital | insufficient for the fund | Funding |
| NCT03117855 | Capecitabine and Y-90 Radioembolization in Treating Patients With Advanced Bile Duct… | Phase 1 | withdrawn | Apr 18, 2017 | City of Hope Medical Center | Company no longer interested in supporting this trial | Sponsor / business decision |
| NCT03026803 | A Study of Oxaliplatin and Capecitabine in Unresectable Metastatic Hepatocellular Cancer | Phase 2 | terminated | Jan 20, 2017 | City of Hope Medical Center | Due to Sorafenib became first line treatment for HCC, the designed treatment became less… | Sponsor / business decision |
| NCT03113604 | Analysis of the Role of Hepatocyte SLAMF3 Receptor and Drug Resistance Proteins (MDR) in…(SLAMF3) | — | withdrawn | Apr 13, 2017 | Centre Hospitalier Universitaire, Amiens | The study has been stopped because no one is | Other (stated, no rule matched) |
| NCT02618447 | 4D Phase Contrast MR: Hypertrophy in Liver Cancer | N/A | terminated | Dec 1, 2015 | Washington University School of Medicine | Insufficient funding | Funding |
| NCT02261844 | Resveratrol and Human Hepatocyte Function in Cancer | Phase 1 / Phase 2 | withdrawn | Oct 10, 2014 | University of Louisville | No funding | Funding |
| NCT01229111 | Cediranib Maleate and Combination Chemotherapy in Treating Patients With Advanced Biliary… | Phase 2 | terminated | Oct 27, 2010 | National Cancer Institute (NCI) | Lack of Drug Supply | Drug supply |
| NCT01405573 | Sorafenib in First-line Treatment of Advanced B Child Hepatocellular Carcinoma(BOOST) | Phase 3 | terminated | Jul 29, 2011 | National Cancer Institute, Naples | lack of enrolment | Enrollment / accrual |
| NCT02323906 | Safety and Efficacy Study of CC-122 Combined With Sorafenib for Primary Liver Cancer | Phase 1 | terminated | Dec 24, 2014 | Celgene | Slow enrollment and business decision. No safety concerns were identified for the study drugs. | Safety / toxicity |
| NCT00510627 | Study Comparing Radio Frequency Ablation Plus Chemotherapy and Chemotherapy Alone in…(Prometheus) | Phase 4 | withdrawn | Aug 2, 2007 | Boston Scientific Corporation | Boston Scientific has decided to close the Study. | Other (stated, no rule matched) |
| NCT00576056 | Effectiveness and Safety Study of TACE Plus Oral Sorafenib for Unresectable HCC | Phase 2 | terminated | Dec 18, 2007 | University of Pittsburgh | Bayer Healthcare is no supplying the study drug | Other (stated, no rule matched) |
| NCT00019604 | Radiofrequency Ablation in Treating Patients With Unresectable Primary or Metastatic… | Phase 2 | terminated | Jan 27, 2003 | National Institutes of Health Clinical Center (CC) | Principal investigator left the institution. | Investigator |
| NCT02772575 | A Study to See if we Can Predict How Your Liver Tumor or Liver Metastases Will Respond to… | — | withdrawn | May 13, 2016 | Memorial Sloan Kettering Cancer Center | not stated | Not stated |
| NCT01163526 | Perfusion CT as a Predictor of Treatment Response in Patients With Hepatic Malignancies | — | terminated | Jul 15, 2010 | Stanford University | accrual | Enrollment / accrual |
| NCT02446379 | Use of the EnLightTM and LightPathTM Imaging Systems in Gastrointestinal Tumour Surgery(CLIO) | — | withdrawn | May 18, 2015 | Lightpoint Medical Limited | Technology licensed to third party. Sponsor did not proceed with study. | Other (stated, no rule matched) |
| NCT02319200 | Primary Prevention Hepatocellular Carcinoma by Metformin(METFOVIR) | Phase 3 | terminated | Dec 18, 2014 | Assistance Publique - Hôpitaux de Paris | Decision of investigator | Investigator |
| NCT01335074 | Temsirolimus + Sorafenib in Advanced Hepatocellular Carcinoma (HCC) | Phase 1 / Phase 2 | withdrawn | Apr 13, 2011 | Philipps University Marburg | not stated | Not stated |
| NCT00427973 | AZD2171 in Treating Patients With Locally Advanced Unresectable or Metastatic Liver Cancer | Phase 2 | terminated | Jan 29, 2007 | National Cancer Institute (NCI) | The study was stopped prior to 2nd stage. | Other (stated, no rule matched) |
| NCT01829971 | A Multicenter Phase I Study of MRX34, MicroRNA miR-RX34 Liposomal Injection | Phase 1 | terminated | Apr 11, 2013 | Mirna Therapeutics, Inc. | Five immune related serious adverse events | Safety / toxicity |
| NCT01964235 | Study of Efficacy and Safety INC280 in Patients With Advanced Hepatocellular Carcinoma | Phase 2 | withdrawn | Oct 17, 2013 | Novartis Pharmaceuticals | Study was cancelled by Sponsor. | Other (stated, no rule matched) |
| NCT01151761 | Phase II SBRT & Chemo for Unresectable Cholangiocarcinoma Followed by Liver… | Phase 2 | terminated | Jun 28, 2010 | Stanford University | Poor accrual | Enrollment / accrual |
| NCT01020812 | Combination SBRT With TACE for Unresectable Hepatocellular Carcinoma | Phase 1 / Phase 2 | terminated | Nov 26, 2009 | Stanford University | enrollment was too low | Enrollment / accrual |
| NCT01652014 | Single or Double Donor Umbilical Cord Blood Transplant in Treating Patients With… | Phase 2 | withdrawn | Jul 27, 2012 | University of Medicine and Dentistry of New Jersey | Funding unavailable | Funding |
| NCT00767234 | Permission to Collect Blood Over Time for Research | — | terminated | Oct 7, 2008 | Stanford University | Accrual issues - Low Accrual | Enrollment / accrual |
| NCT00767936 | Viral & Host Factors Associated With Hepatitis B Virus-related Hepatocellular Carcinoma | — | terminated | Oct 7, 2008 | Stanford University | not stated | Not stated |
| NCT01744639 | Analysis of Body Composition in Patients With Hepatocellular Carcinoma in Radioablation | N/A | withdrawn | Dec 7, 2012 | Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran | Unable to find patients | Other (stated, no rule matched) |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Sep 1, 2017source: clinicaltrials